This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herbst, R. S. Articles by Johnson, B. E. Search for Related Content PubMed PubMed Citation Articles by Herbst, R. S. Articles by Johnson, B. E.

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Authors' Affiliations: ¹ The University of Texas M. D. Anderson Cancer Center, Houston, Texas; ² UC Davis Cancer Center, Sacramento, California; ³ Cedars-Sinai Cancer Center, Los Angeles, California; ⁴ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; ⁵ University of Wisconsin, Madison, Wisconsin; ⁶ Arizona Cancer Center, Tucson, Arizona; ⁷ Memorial-Sloan Kettering Cancer Center, New York, New York; ⁸ Premiere Oncology of Arizona, Scottsdale, Arizona; ⁹ Dana-Farber Cancer Institute, Boston, Massachusetts; and ¹⁰ Genentech, Inc., South San Francisco, California

Requests for reprints: Bruce E. Johnson, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1234, Boston, MA 02115. Phone: 617-632-4790; Fax: 617-632-5786; E-mail: bruce_johnson{at}dfci.harvard.edu.

Purpose: Pertuzumab, a first-in-class human epidermal receptor 2 (HER2) dimerization inhibitor, is a humanized monoclonal anti-HER2 antibody that binds HER2's dimerization domain and inhibits HER2 signaling. Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non–small cell lung cancer (NSCLC).

Experimental Design: Patients with previously treated NSCLC accessible for core biopsy and naive to HER pathway inhibitors were treated with pertuzumab i.v. once every 3 weeks. Tumor assessments were done at 6 and 12 weeks and then every 3 months thereafter. The primary efficacy end point was overall response rate by Response Evaluation Criteria in Solid Tumors. Measurement of tumor glucose metabolism (SUV_max) by F-18-fluorodeoxyglucose positron emission tomography was used as an exploratory pharmacodynamic marker of drug activity.

Results: Of 43 patients treated with pertuzumab, no responses were seen; 18 of 43 (41.9%) and 9 of 43 (20.9%) patients had stable disease at 6 and 12 weeks, respectively. The median and 3-month progression-free survival rates (PFS) were 6.1 weeks (95% confidence interval, 5.3-11.3 weeks) and 28.4% (95% confidence interval, 14.4-44.2%), respectively. Of 22 patients who underwent F-18-fluorodeoxyglucose positron emission tomography, six (27.3%) had a metabolic response to pertuzumab as evidenced by decreased SUV_max. These patients had prolonged PFS (HR = 0.11, log-rank P value = 0.018) compared with the 16 patients who had no metabolic response. Four patients (9.3%) experienced a grade 3/grade 4 adverse event judged related to pertuzumab; none exhibited grade 3/grade 4 cardiac toxicity.

Conclusions: Pertuzumab is well tolerated as monotherapy. Pharmacodynamic activity correlated with prolonged PFS was detected in a moderate percentage of patients (27.3%). Further clinical development of pertuzumab should focus on rational combinations of pertuzumab with other drugs active in NSCLC.

This article has been cited by other articles:

				C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283. [Abstract] [Full Text] [PDF]